fat-storing white adipocytes into fat-burning adipocytes (brown-like, brite or beige). MicroRNAs are attractive drug candidates for complex diseases like obesity, as they can modulate the expression of gene networks. AptamiR is also developing drug delivery approaches that can specifically target microRNA modulators to adipose tissue. It provides treatment for human obesity by targeting peripheral white and brown adipose tissues and is based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food that enables patients to get the excess fat removed from their body.

AptamiR Therapeutics was established in 2012 and is headquartered in Austin, Texas.